Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials

DaxibotulinumtoxinA for Injection (DAXI) is a novel botulinum toxin type A product containing daxibotulinumtoxinA with a stabilizing excipient peptide (RTP004). DAXI immunogenicity was assessed in three phase 3 glabellar line studies (two placebo-controlled, single-dose studies and an open-label rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallagher, Conor J., Bowsher, Ronald R., Clancy, Amanda, Dover, Jeffrey S., Humphrey, Shannon, Liu, Yan, Prawdzik, Gregg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862169/
https://www.ncbi.nlm.nih.gov/pubmed/36668880
http://dx.doi.org/10.3390/toxins15010060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862169/
https://www.ncbi.nlm.nih.gov/pubmed/36668880
http://dx.doi.org/10.3390/toxins15010060

Ejemplares similares